Brittany T Straka1, Claudia E Ramirez1, James B Byrd1, Elizabeth Stone1, Alencia Woodard-Grice1, Hui Nian2, Chang Yu2, Aleena Banerji3, Nancy J Brown4. 1. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn. 2. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tenn. 3. Massachussetts General Hospital, Boston, Mass. 4. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn. Electronic address: Nancy.j.brown@vanderbilt.edu.
Abstract
BACKGROUND: The B2 receptor antagonist icatibant is approved for treatment of attacks of hereditary angioedema. Icatibant has been reported to decrease time-to-resolution of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema in 1 study of European patients. OBJECTIVE: We sought to test the hypothesis that a bradykinin B2 receptor antagonist would shorten time-to-resolution from ACE inhibitor-associated angioedema. METHODS:Patients with ACE inhibitor-associated angioedema (defined as swelling of lips, tongue, pharynx, or face during ACE inhibitor use and no swelling in the absence of ACE inhibitor use) were enrolled at Vanderbilt University Medical Center from October 2007 through September 2015 and at Massachusetts General Hospital in 2012. C1 inhibitor deficiency and patients with bowel edema only were excluded. Patients were randomized within 6 hours of presentation to subcutaneous icatibant 30 mg or placebo at 0 and 6 hours later. Patients assessed severity of swelling using a visual analog scale serially following study drug administration or until discharge. RESULTS:Thirty-three patients were randomized and 31 received treatment, with 13 receiving icatibant and 18 receivingplacebo. One patient randomized to icatibant did not complete the visual analog scale and was excluded from analyses. Two-thirds of patients were black and two-thirds were women. Time-to-resolution of symptoms was similar in placebo and icatibant treatment groups (P = .19 for the primary symptom and P > .16 for individual symptoms of face, lip, tongue, or eyelid swelling). Frequency of administration of H1 and H2 blockers, corticosteroids, and epinephrine was similar in the 2 treatment groups. Time-to-resolution of symptoms was similar in black and white patients. CONCLUSIONS: This study does not support clinical efficacy of a bradykinin B2 receptor antagonist in ACE inhibitor-associated angioedema.
RCT Entities:
BACKGROUND: The B2 receptor antagonist icatibant is approved for treatment of attacks of hereditary angioedema. Icatibant has been reported to decrease time-to-resolution of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema in 1 study of European patients. OBJECTIVE: We sought to test the hypothesis that a bradykininB2 receptor antagonist would shorten time-to-resolution from ACE inhibitor-associated angioedema. METHODS:Patients with ACE inhibitor-associated angioedema (defined as swelling of lips, tongue, pharynx, or face during ACE inhibitor use and no swelling in the absence of ACE inhibitor use) were enrolled at Vanderbilt University Medical Center from October 2007 through September 2015 and at Massachusetts General Hospital in 2012. C1 inhibitor deficiency and patients with bowel edema only were excluded. Patients were randomized within 6 hours of presentation to subcutaneous icatibant 30 mg or placebo at 0 and 6 hours later. Patients assessed severity of swelling using a visual analog scale serially following study drug administration or until discharge. RESULTS: Thirty-three patients were randomized and 31 received treatment, with 13 receiving icatibant and 18 receiving placebo. One patient randomized to icatibant did not complete the visual analog scale and was excluded from analyses. Two-thirds of patients were black and two-thirds were women. Time-to-resolution of symptoms was similar in placebo and icatibant treatment groups (P = .19 for the primary symptom and P > .16 for individual symptoms of face, lip, tongue, or eyelid swelling). Frequency of administration of H1 and H2 blockers, corticosteroids, and epinephrine was similar in the 2 treatment groups. Time-to-resolution of symptoms was similar in black and white patients. CONCLUSIONS: This study does not support clinical efficacy of a bradykininB2 receptor antagonist in ACE inhibitor-associated angioedema.
Authors: John B Kostis; Harold J Kim; James Rusnak; Thomas Casale; Allen Kaplan; Jonathan Corren; Elliott Levy Journal: Arch Intern Med Date: 2005-07-25
Authors: Murat Baş; Jens Greve; Klaus Stelter; Miriam Havel; Ulrich Strassen; Nicole Rotter; Johannes Veit; Beate Schossow; Alexander Hapfelmeier; Victoria Kehl; Georg Kojda; Thomas K Hoffmann Journal: N Engl J Med Date: 2015-01-29 Impact factor: 91.245
Authors: Lawrence M Lewis; Charles Graffeo; Pascal Crosley; Howard A Klausner; Carol L Clark; Anthony Frank; James Miner; Ryan Iarrobino; Yung Chyung Journal: Ann Emerg Med Date: 2014-08-30 Impact factor: 5.721
Authors: Jonathan A Bernstein; Joseph J Moellman; Sean P Collins; Kimberly W Hart; Chris J Lindsell Journal: Ann Allergy Asthma Immunol Date: 2015-01-16 Impact factor: 6.347
Authors: C Emanueli; E F Grady; P Madeddu; M Figini; N W Bunnett; D Parisi; D Regoli; P Geppetti Journal: Hypertension Date: 1998-06 Impact factor: 10.190
Authors: Donald R Miller; Susan A Oliveria; Dan R Berlowitz; Benjamin G Fincke; Paul Stang; David E Lillienfeld Journal: Hypertension Date: 2008-04-14 Impact factor: 10.190
Authors: Scott A Hubers; Kevin Kohm; Shouzuo Wei; Chang Yu; Hui Nian; Ryan Grabert; Daniel J Sexton; Nancy J Brown Journal: J Allergy Clin Immunol Date: 2018-07-21 Impact factor: 10.793
Authors: Lauren B Arendse; A H Jan Danser; Marko Poglitsch; Rhian M Touyz; John C Burnett; Catherine Llorens-Cortes; Mario R Ehlers; Edward D Sturrock Journal: Pharmacol Rev Date: 2019-10 Impact factor: 25.468